These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 6154099

  • 1. Leukocyte adherence inhibition response to murine sarcoma virus-induced tumors. I. Cell requirements, specificity, lack of H-2 restriction, and role of antibody.
    Mortensen RF, Elson LM.
    J Immunol; 1980 May; 124(5):2316-23. PubMed ID: 6154099
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Rejection of non viral tumors caused by infection with murine sarcoma virus].
    Basombrio MA.
    Medicina (B Aires); 1977 May; 37(2):127-32. PubMed ID: 197370
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of specificity for viral and H-2 antigens by anomalous T killer cells generated in murine leukocyte cultures.
    Shain B, Holt CA, Lilly F.
    J Immunol; 1982 Aug; 129(2):722-9. PubMed ID: 6177779
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cell-mediated immune reactions directed against syngeneic methylcholanthrene-induced mouse sarcomas: low reproducibility of the results obtained with the tube modification of leukocyte adherence inhibition assay.
    Simová J, Bubeník J.
    Neoplasma; 1979 Aug; 26(5):635-9. PubMed ID: 392326
    [Abstract] [Full Text] [Related]

  • 9. Regulation of cell-mediated immunologic reactivity to Moloney Murine sarcoma virus-induced tumors. III. Further characterization of tumor-specific serum blocking factors.
    Halliday WJ, Koppi TA, McKenzie IF.
    J Natl Cancer Inst; 1982 Oct; 69(4):939-44. PubMed ID: 6750199
    [Abstract] [Full Text] [Related]

  • 10. Immunity to murine sarcoma virus-inducted tumors. I. Specific T lymphocytes active in macrophage migration inhibition and lymphocyte transformation.
    Gorczynski RM.
    J Immunol; 1974 May; 112(5):1815-25. PubMed ID: 4361977
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhancement of normal lymphocyte cytotoxicity by sera with high antibody titers against H-2 or virus-associated antigens.
    Harada M, Pearson G, Pettigrew H, Redmon L, Orr T.
    Cancer Res; 1973 Nov; 33(11):2886-93. PubMed ID: 4583975
    [No Abstract] [Full Text] [Related]

  • 13. Leukocyte adherence inhibition response to murine sarcoma virus-induced tumors. II. Requirement for T-cell subpopulations and macrophages.
    Sarlo KT, Mortensen RF.
    Cell Immunol; 1983 Jul 15; 79(2):211-9. PubMed ID: 6307531
    [Abstract] [Full Text] [Related]

  • 14. Suppression of the leukocyte adherence inhibition response to murine-sarcoma-virus-induced tumors by tumor-associated suppressor cells.
    Mortensen RF, Elson LM.
    Oncology; 1980 Jul 15; 37(6):406-10. PubMed ID: 6253859
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systemic and in situ natural killer activity in C57BL/6N and CBA/N mice bearing murine sarcoma virus-induced regressor tumors.
    Gerson JM, Holden HT, Herberman RB.
    J Natl Cancer Inst; 1980 Nov 15; 65(5):905-7. PubMed ID: 6253708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.